The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH)
Publications
Estevinho F, Soares M, Azevedo I, Queiroga H, Parente B, Brito U, Teixeira E, Sotto-Mayor R, Araújo A
Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study.
Cancer management and research 2012;4;91-7 — 2012 — 91-7
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Mar 20;27;1405-12 — 2009 Mar 20 — 1405-12
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
The New England journal of medicine 2006 Dec 14;355;2542-50 — 2006 Dec 14 — 2542-50